F S&P 500
5,254.50 +15.50 (+0.30%) F Dow Jones
39,621.00 +85.00 (+0.21%) F Nasdaq
18,283.25 +68.75 (+0.38%) E-mini Russell 2000 Index Futur
2,091.80 +7.70 (+0.37%) Petróleo
79.82 +0.56 (+0.71%) Oro
2,379.50 +39.20 (+1.67%)
Molecular Partners AG (MOLN)
Molecular Partners AG
Wagistrasse 14
Schlieren 8952
Switzerland
41 44 755 77 00
https://www.molecularpartners.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 167
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Patrick Amstutz Ph.D. | Co-Founder, CEO, Member of Management Board & Director | 729.01k | N/D | 1975 |
| Dr. Michael Tobias Stumpp Ph.D. | Co-Founder, Executive VP of Projects & Member of Management Board | N/D | N/D | 1972 |
| Mr. Robert Hendriks | Senior VP of Finance | N/D | N/D | N/D |
| Mr. Alexander Zurcher | COO & Member of Management Board | N/D | N/D | 1975 |
| Ms. Renate Gloggner | Executive VP of People & Community and Member of Management Board | N/D | N/D | 1970 |
| Mr. Daniel Steiner Ph.D. | Senior Vice President of Research & Technology | N/D | N/D | N/D |
| Mr. Seth D. Lewis | Senior Vice President of Investor Relations, Communications & Strategy | N/D | N/D | N/D |
| Mr. Michael Pitzner | General Counsel, Compliance Officer, Senior VP Legal & Business Development | N/D | N/D | N/D |
| Dr. Pamela A. Trail Ph.D. | Strategic Consultant | N/D | N/D | 1956 |
| Ms. Anne Goubier D.V.M., Ph.D. | Senior Vice President of Research & Early Development | N/D | N/D | N/D |
Descripción
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Gestión corporativa
La calificación ISS Governance QuickScore de Molecular Partners AG a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
